483 results about "Infective disorder" patented technology

The invention discloses a capture probe group for detecting pathogenic microorganisms and application of the capture probe group. The nucleic acid sequence of the capture probe group comprises a sequence as shown in SEQ ID NO. 1 to SEQ ID NO. 101. The capture probe group can cover and detect 119 types of bacteria, 32 types of fungi, 41 types of DNA viruses and 71 types of RNA viruses and covers common infectious disease pathogens, the kit containing the capture probe can cover and detect 88 types of drug-resistant and virulence genes, the detection performance of pathogenic microorganisms is greatly improved, and the sensitivity and specificity are improved.

The invention discloses a Graisseria parasuis three-component subunit vaccine and a preparation method thereof, and belongs to the technical field of biology. The vaccine comprises three kinds of antigen proteins of the Gleisseria parasuis in an immunizing dose and a pharmaceutically acceptable adjuvant, and the amino acid sequences of the three kinds of antigen proteins are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The invention further discloses a preparation method of the vaccine. The three-component subunit vaccine provided by the invention has cross protection force on infection of type-4 and type-5 Graisseria parasuis, has an excellent immune protection effect, and is expected to play a better role in prevention and control of infectious diseases caused by the Graisseria parasuis.

The invention belongs to the technical field of medicines, and particularly relates to application of sesquiterpenoids and / or pharmaceutically acceptable salts thereof in preparation of medicines for treating or preventing infectious diseases caused by staphylococcus aureus. The invention relates to the field of medicines, in particular to application in preparation of medicines for treating or preventing infectious diseases caused by drug-sensitive staphylococcus aureus or drug-resistant staphylococcus aureus. The structure of the sesquiterpenoids is shown as a formula I in the specification. The sesquiterpenoids applied in the invention are derived from rattan chrysanthemum, the source is wide, and the production cost is low. The sesquiterpenoids shown in the formula I have a very good activity inhibition effect on staphylococcus aureus for the first time, and the sesquiterpenoids have a very good activity inhibition effect on staphylococcus aureus with drug sensitivity, drug medium or drug resistance.

The invention discloses an antibacterial peptide simulant based on adamantane modification and application of the antibacterial peptide simulant. The preparation method comprises the following steps: performing amide condensation on Fmoc amino acid to obtain a compound of which the carboxyl terminal is modified by amantadine or Boc protected aliphatic amine, and then removing an Fmoc group by piperidine to obtain a series of amantadine modified crude products and Boc protected aliphatic amine modified intermediate compounds; the intermediate compound is subjected to amide condensation to obtain a compound of which the amino terminal is further modified by adamantanic acid, then other protecting groups are cracked by trifluoroacetic acid to obtain a series of adamantanic acid modified crude products, and the crude products are purified to obtain the adamantane modified peptidomimetic. The adamantane modified peptidomimetic is used for preparing drugs for treating infectious diseases caused by sensitive bacteria and drug-resistant bacteria, has efficient antibacterial activity and low toxicity, and is not influenced by a traditional drug-resistant mechanism.

A system includes a memory that stores instructions; and a processor that executes the instructions. When executed by the processor, the instructions cause the system to: obtain real-time data of potential routes for transporting a patient with an infectious disease within a hospital; apply a prediction model to the real-time data to minimize the potential for spreading the infectious disease while transporting the patient; and suggest a route among the potential routes with a minimized potential for spreading the infectious disease.

The invention belongs to the technical field of medicines, and particularly relates to a benzothiophene compound as well as a pharmaceutical composition, a pharmaceutical preparation and application thereof. The benzothiophene compound has a structure as shown in a formula (I), has a very strong excitation effect on an STING-mediated interferon signal channel, can be used as a small-molecule STING agonist, and is used for clinical treatment (especially immunotherapy) of tumors or infectious diseases. # imgabs0 #

The invention discloses an intelligent prevention and control and early warning system for children infectious diseases, and relates to the field of data analysis, and the main scheme is as follows: calculating a disease infection risk index # imgabs4 # according to an environmental risk index # imgabs0 #, a physiological risk comprehensive index # imgabs1 #, a disease transmission risk index # imgabs2 # and a comprehensive infection index # imgabs3 #; the children infection risk is judged according to the disease infection risk index # imgabs5 # and the infection risk threshold value, the problem that the physical conditions, living environments and behavioral habits of all children are different is solved, the development trend of infected diseases is judged by calculating the proportion of the number of diseased children, the development trend of the diseases in the whole children group can only be judged from the macroscopic level, and the development trend of the infected diseases in the whole children group is judged. And the method cannot go deep into an individual level and is difficult to meet individual differentiation prevention and control requirements.

The invention belongs to the technical field of biological detection, and particularly discloses a targeted sequencing primer group and a kit for detecting common pathogens of children and drug-resistant genes thereof. The primer group comprises 145 primer pairs of common children pathogen primer groups and 67 primer pairs of drug-resistant gene primer groups of the common children pathogen primer groups. According to the kit provided by the invention, nucleic acid in a clinical sample is directly extracted, 212 pairs of specific primers are adopted to realize multi-targeted amplification of a pathogen target area, a high-throughput sequencing platform is adopted to accurately identify pathogens and drug-resistant mutant genes thereof, 72 common children pathogens and drug-resistant genes thereof can be detected at the same time, and the kit has a wide application prospect. More accurate diagnosis information is provided for clinic, a key technical support is provided for early-stage accurate treatment of children infectious diseases, and the technical problems that in the prior art, in children pathogen detection, the detection speed is low, the number of missed detection is large, and the drug-resistant blind area is large are solved.

The present invention provides binding agents that specifically bind to CD8+KIR+ T regulatory cells and their use in the treatment of diseases or disorders, such as an inflammatory disease, an autoimmune disease, cancer, or an infectious disease.

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The invention discloses a method for in-vitro induction of T cell immune memory differentiation and application, CD8 + T memory differentiation can be enhanced by verifying in-vitro itaconic acid and derivative supplement thereof, and then anti-tumor and anti-infection immune response is enhanced after in-vivo feedback. The invention can be used in malignant tumors and infectious diseases to enhance the curative effect of T cell adoptive therapy.

The invention provides application of thalictriine in preparation of antiviral drugs, and belongs to the technical field of antiviral drugs. The invention proves that the thalictriine has an inhibition effect on various common infectious disease viruses of domestic pigs from a cellular level, and particularly has a remarkable inhibition effect on proliferation of African swine fever virus (ASFV), porcine reproductive and respiratory syndrome virus (PRRSV), porcine circovirus type 2 (PCV2) and porcine epidemic diarrhea virus (PEDV) in vitro. The invention also discloses an antiviral composition consisting of the active ingredient thalictriine or the pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and / or excipient, and discloses an application of the composition in preparation of a virus infection inhibitor and / or a pharmaceutical preparation for preventing and / or treating virus infectious diseases. And a basis is provided for developing novel broad-spectrum antiviral drugs.

The invention provides application of magnoline in preparation of antiviral drugs, and belongs to the technical field of antiviral drugs. It is proved from the cellular level that magnoline has the inhibiting effect on various common infectious disease viruses of domestic pigs, and particularly has the remarkable inhibiting effect on proliferation of African swine fever virus (ASFV), porcine reproductive and respiratory syndrome virus (PRRSV), porcine circovirus type 2 virus (PCV2) and porcine epidemic diarrhea virus (PEDV) in vitro. The invention also discloses an antiviral composition consisting of the active component magnoline or the pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and / or excipient, and discloses application of the composition in preparation of a virus infection inhibitor and / or a pharmaceutical preparation for preventing and / or treating virus infectious diseases. And a basis is provided for developing novel broad-spectrum antiviral drugs.

The invention discloses a gamma delta T cell efficient amplification method and application, and belongs to the technical field of cell biology. The amplification method comprises the following steps: separating PBMC (peripheral blood mononuclear cells) by adopting a density gradient centrifugation method, carrying out initial culture through a polylysine coated container, carrying out three-stage dynamic stimulation, combining with an X-VIVO 15 culture medium of 5-8% autoserum, and finally carrying out anti-gamma delta TCR magnetic bead separation to obtain high-purity cells. Through collaborative optimization of stepped factor combination, staged container coating and a low-serum system, the amplification multiple of the gamma delta T cells reaches 150-180 times, the purity is larger than or equal to 90% after purification, the cytotoxicity and the survival ability are remarkably improved, the gamma delta T cells can be efficiently used for immunotherapy of tumors and infectious diseases, and stable technical support is provided for clinical transformation of the gamma delta T cells.

The present application discloses different classes of mitochondrial uncoupling compounds having significantly improved pharmacokinetic properties and conventional mitochondrial uncoupling compounds, pharmaceutical compositions containing the compounds and / or prodrugs, and diseases that are useful in the treatment of diseases associated with mitochondrial dysfunction or benefits by modulation of mitochondrial activity. Methods of using the compounds, prodrugs, and pharmaceutical compositions in treatment of diseases, including diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), mitochondrial genetic diseases, neurodegenerative diseases, cancer, autoimmune diseases, and infectious diseases.

The present disclosure relates to an imidazole lipid and a use thereof. Specifically, provided are a compound represented by formula I or a salt thereof, and a lipid particle or a pharmaceutical composition containing the compound. The compound can be used as a delivery system, and is used for preparing drugs for preventing and / or treating cancers, infectious diseases, autoimmune diseases, neurodegenerative diseases, inflammation, etc. The definition of each group in formula (I) is as described in the description.

The invention relates to a TANK binding kinase 1 inhibitor and pharmaceutical application thereof, and belongs to the technical field of biological medicine. The TANK binding kinase 1 inhibitor is a compound ITA-9. The invention also provides an application of the compound ITA-9 in preparation of a pharmaceutical composition for preventing and / or treating TBK1 activity-related diseases, wherein the TBK1 activity-related diseases comprise infectious diseases, autoimmune diseases, metabolic diseases or cancers and the like. The invention discloses an application of a compound ITA-9 as a TANK binding kinase 1 (TBK1) inhibitor in preparation of a pharmaceutical composition for preventing and / or treating TBK1 activity related diseases for the first time. The compound has the potential of being developed into TBK1 inhibitor drugs and drugs for treating TBK1-related diseases such as infectious diseases, autoimmune diseases, metabolic diseases and cancers, provides a new treatment drug for clinic, and has good clinical application value and wide application prospects.

The invention provides an anti-influenza B virus nano antibody and application thereof, the nano antibody comprises a heavy chain variable region, the heavy chain variable region comprises CDR1, CDR2 and CDR3, and the CDR3 of the heavy chain variable region is selected from an amino acid sequence as shown in SEQ ID NO: 8 or SEQ ID NO: 16. The nano antibody is obtained through a multi-antigen cross immunization and panning method, the nano antibody can be specifically combined with Colorado / 06 / 2017 and Florida / 4 / 2006 influenza B viruses, the sensitivity is high, the specificity is high, and the phenomenon of missing detection in clinical detection can be avoided in clinical application. The nano antibody can be efficiently expressed through prokaryotic cells, and compared with eukaryotic mammalian cell expression of a traditional antibody, the nano antibody is lower in production cost and more beneficial to popularization and application in detection of infectious diseases.

The present invention relates to compounds having cyclin-dependent kinase (CDK)-inhibitory functions and / or pharmaceutically acceptable salts thereof, the use of these compounds as pharmaceutically active agents, especially for the prophylaxis and / or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing such compounds.

NEO-201, an antibody that specifically binds to glycosylated peptides carrying core-1 and / or extended core-1 O-glycans comprised in CEACAM5 and CEAMCAM6, but does not bind to non-glycosylated CEACAM5 or non-glycosylated CEAMCAM6, has surprisingly shown to bind to and kill granulocyte myeloid-derived suppressor cells (gMDSC). The gMDSC is known to inhibit innate immunity in different cancers and infectious diseases, as well as other conditions. Based thereon, there is provided the use of NEO-201, alone or in combination, for the treatment of cancer and infectious diseases, as well as other conditions in which gMDSC inhibits innate immunity against the disease. The methods optionally include detecting the gMDSC before, during, or after the NEO-201 treatment. Diagnostic methods, therapeutic methods, and combination therapies using NEO-201, optionally in combination with another agent, to eliminate gMDSC and disease cells are also described.

The invention relates to a compound probiotic formula, a preparation and application of the compound probiotic formula. The compound probiotic formula is prepared from bifidobacterium animalis HN019, bifidobacterium animalis Bb-12, bifidobacterium breve M-16V, lactobacillus rhamnosus HN001 and lactobacillus acidophilus NCFM. The ratio of the viable count of the bifidobacterium animalis HN019 to the viable count of the bifidobacterium animalis Bb-12 to the viable count of the bifidobacterium breve M-16V to the viable count of the lactobacillus rhamnosus HN001 to the viable count of the lactobacillus acidophilus NCFM is 2.5 to 1.2 to 1.3 to 2.5 to 2.5. The traditional Chinese medicine composition has the advantages of helping to establish intestinal flora balance, improving immunity, preventing infectious diseases, regulating immune balance, preventing and relieving eczema and allergy, bidirectionally regulating diarrhea and constipation, relieving gastrointestinal function discomfort symptoms, improving poor appetite, anorexia and dyspepsia, improving children crying and screaming at night and poor sleep, improving children growth and development retardation, and improving children immunity. Social emotion behaviors of children are improved, and attention deficits are improved; the probiotic composition can coexist and symbiotic, induces an organism to establish intestinal flora balance, relieves food allergy symptoms, and improves social emotion problems caused by food allergy.

This invention relates to anti-CD40 antibodies or antigen-binding fragments thereof that specifically recognize and weakly activate CD40 molecules in humans, cynomolgus monkeys, and mice, as well as immunoconjugates, pharmaceutical compositions, and combination products comprising said anti-CD40 antibodies or antigen-binding fragments thereof. The invention also relates to nucleic acids encoding said anti-CD40 antibodies or antigen-binding fragments thereof and host cells comprising said nucleic acids, and methods for preparing said anti-CD40 antibodies or antigen-binding fragments thereof. Furthermore, the invention relates to the use of said anti-CD40 antibodies or antigen-binding fragments thereof in the prevention or treatment of tumors or infectious diseases in subjects.

Antibody molecules that specifically bind to NKp30 are disclosed. The anti-NKp30 antibody molecules can be used to treat, prevent and / or diagnose cancerous, autoimmune or infectious conditions and disorders.

Compounds and methods are provided for inhibiting a PI4-kinase. Methods of treating a pathogen infection and methods of treating cancer are also provided. The PI4-kinase inhibitor can be a compound that is a 5-aryl or heteroaryl-thiazole, e.g., as described herein. In certain embodiments, the PI4-kinase inhibitor is a substituted 2-amino-5-phenylthiazole or substituted 2-amino-5-pyridylthiazole compound. In some embodiments, the compounds have broad spectrum anti-infective activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of treating a subject for cancer using a PI4-kinase inhibitor. Aspects of the methods include inhibiting PI4-kinase in a cancer cell to reduce cellular proliferation.

The invention discloses a blood drawing device for preventing cross infection of blood infectious diseases, and relates to the field of infection department doctors, a reserved blood drawing needle assembly is nested on the outer side of a reserved external butt joint piece, and the reserved external butt joint piece is in butt joint with an external blood drawing structure; the end of the reserved external butt-joint piece is fixedly connected with a built-in fixed partition assembly, the inner end of the reserved external butt-joint piece is rotationally connected with a movable butt-joint rotating piece, and the movable butt-joint rotating piece corresponds to the outer side of the built-in fixed partition assembly in position. According to the blood drawing device capable of preventing cross infection of the blood infectious diseases, self-adaptive disinfection treatment is carried out on the reserved blood drawing needle assembly and the reserved external butt joint piece in the disassembly process in cooperation with an auxiliary self-supply structure; the possibility of cross infection of blood infectious diseases is prevented through self-release disinfectant supply, and self-adaptive disinfection treatment is stably carried out according to the previous operation step.

The invention discloses application of a cyclic peptide compound BIM 23042 or a preparation thereof in preparation of medicines for treating bacterial infectious diseases, and belongs to the technical field of medicines. The invention discloses a cyclic peptide compound BIM 23042 as an antibiotic synergist for the first time, and the cyclic peptide compound BIM 23042 is used for treating bacterial infectious diseases. According to the application disclosed by the invention, the cyclopeptide compound BIM 23042 and polymyxin are combined for use, so that the growth of gram-negative bacteria can be effectively and synergistically inhibited. The combined medication scheme shows a remarkable advantage in coping with acinetobacter baumannii. The cyclic peptide compound BIM 23042 disclosed by the invention has an anti-infection capability, and the anti-infection capability is specifically shown as reducing the inflammatory response of macrophage RAW 264.7 induced by LPS (Lipopolysaccharide) and also reducing the apoptosis of the macrophage RAW 264.7 caused by the LPS. The invention provides a new perspective for developing a novel drug-resistant gram-negative bacterium prevention and control strategy, and also provides a new treatment scheme for coping with bacterial infection.

The invention discloses an application of S100A8 / A9 in evaluating the severity of infectious diseases. Specifically disclosed is the use of a biomarker (S100A8 / A9) and / or a substance for detecting the biomarker in the preparation of a product for evaluating the severity of infectious diseases. By detecting the level of S100A8 / A9 in serum or plasma, the severity of infectious diseases is rapidly and accurately evaluated, the evaluation process is simplified, the accuracy is improved, and the kit is suitable for various infectious diseases. The biomarker is high in sensitivity and good in specificity, decision support can be provided for clinicians by evaluating the severity of the illness state, a treatment scheme can be provided for patients more accurately, the treatment effect and the living quality of the patients can be improved, meanwhile, optimal disease management is achieved, the medical burden on families and the society of the patients is relieved, and the application prospect is wide. Good and wide clinical application values are realized.

The application discloses a fusion protein for preventing and treating various pathogenic Pasteurellaceae bacterial infections, a nucleic acid vaccine and application thereof. The fusion protein comprises six antigens rplE, rpsC, rpsE, EF-Tu, DnaK and EF-G or three antigens EF-Tu, DnaK and EF-G, and the antigens are highly conservative in various Pasteurellaceae bacteria. The application further provides a recombinant nucleic acid molecule encoding the fusion protein, an immunogenic composition containing the same and a recombinant vaccine. The vaccine can induce broad-spectrum cross immune protection and is used for preventing and treating infectious diseases caused by Pasteurella multocida, Haemophilus parasuis, Mannheimia haemolytica, Haemophilus influenzae and Haemophilus paragallinarum.

The present Invention relates to a newly designed product, i.e. substance (B+C) that combines two different mechanisms of action that allow the control of aldosterone synthesis and secretion without compromising the metabolism of cortisol (corticosterone In rats) in the.tone glomerulosa of the adrenal gland. The innovative design of the described molecule enables ths individual use of substance (B+C) in the treatment of diseases such as hyper and hypo aldosteronism, Conn's syndrome and cytokine storm caused by Covid infection or as co-therapy with corticosteroids in the treatment of a whole range of immunological diseases. The innovative design of Substance (8+C) has an additional practical and economic advantage because the patient receives both components of substance (B+C) simultaneously with just one application, regardless of the medicine formulation. This not only simplifies the medicine synthesis, dosing and clinical research, but also the application of the medicine in clinical practice. For successful and selective control of aldosterone synthesis, which in nature also means selective control of blood pressure, it was necessary to combine the two substances described in order to ensure action in patients with elevated and / or towered blood pressure with one application of Substance (B+C). This feature of Substance (B+C) is important, especially in the treatment of patients with permanently impaired aldosterone synthesis, such as Conn's disease and similar autoimmune diseases, or in combmatton with corticosteroids where prolonged or repeated corticosteroid therapy is indicated. Finally, this invention is extremely important because It enables the safe treatment of a large group of patients with hypertension who also have secondary diseases of the immune system, various inflammations or viral Infections such as Covid where corticosteroid therapy is indicated, but difficult to implement in practice due to the negative effect of corticosteroids on blood pressure.

The invention discloses a swelling microneedle patch and a preparation method thereof. The swelling microneedle patch comprises a backing and a swelling microneedle array adhered to the backing, the swelling microneedle array comprises a plurality of microneedles; the microneedle is in the shape of a cone or a rectangular pyramid; the height of the microneedle is 100 to 1000 [mu] m; the diameter of the tip end of the microneedle is 5-30 microns; the diameter of the bottom of the microneedle is 50-500 [mu] m; and the center-to-center distance between every two adjacent microneedles is 50-2000 microns. The swelling microneedle patch provided by the invention can overcome the barrier action of cuticle to penetrate subcutaneously and absorb subcutaneous tissue interstitial fluid, and is simple in preparation process, low in cost and high in universality. The patch is combined with a colloidal gold lateral chromatography test strip, so that the limitations that in-vitro diagnosis of infectious diseases depends on a blood sample, professional medical personnel are needed for operation, the subject compliance is poor and the like can be solved, and the patch is suitable for rapid screening and diagnosis of the infectious diseases.